GLP-1
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Patients will get same-day delivery and access to treatments like GLP-1s and hormone therapies.
Personify’s Transform Weight Management program will provide LucyRx members with personalized, coach-led guidance, incentives and assets to help manage their weight and medication.
Americans with a prescription will have access to Novo Nordisk's obesity drug Wegovy through the Hims & Hers platform for $599 monthly.
Lark's cardiometabolic care coaching programs will be made accessible through CVS Caremark's Point Solutions Management program.
The partnership will give customers easy access to GLP-1 class drugs and other anti-obesity medications.
Two U.S. senators and the Partnership for Safe Medicines sent letters to the FDA, raising concerns that the ad fails to disclose safety and side effect information required in pharmaceutical advertising.
The company says the layoffs occurred due to the need to focus its workforce on critical areas of the business.
The expansion includes prescribing capabilities and entry into the direct-to-consumer market.
The aim is to provide long-term behavioral change focusing on weight loss and maintenance.